DeepMed Research

ONO PHARMACEUTICAL CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: $7.1B

Website: https://www.ono.co.jp/

Clinical Trials

Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: ONO-2910

First Posted Date: 2020-08-07

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 80

Registration Number: NCT04504760

Locations: 🇯🇵
Tokyo Clinical Site 01, Tokyo, Japan

Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: FOY-305

First Posted Date: 2020-06-30

Last Posted Date: 2024-04-09

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 14

Registration Number: NCT04451083

Locations: 🇯🇵
Fukuoka Clinical Site 01, Fukuoka, Japan

ONO-7913 Phase I Study (ONO-7913)

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Biological: ONO-7913

First Posted Date: 2020-05-27

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 7

Registration Number: NCT04403308

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: ONO-4685
Biological: Placebo
Biological: KLH
Biological: KLH, ONO-4685
Biological: KLH, placebo

First Posted Date: 2019-09-06

Last Posted Date: 2024-05-03

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 78

Registration Number: NCT04079062

Locations: 🇯🇵
Fukuoka Clinical Site, Hakata, Fukuoka, Japan

A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: ONO-7684
Drug: ONO-7684 Placebo

First Posted Date: 2019-04-18

Last Posted Date: 2019-12-09

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 72

Registration Number: NCT03919890

Locations: 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom

Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788

Phase 1

Completed

Conditions: Acromegaly

Interventions: Drug: ONO-5788
Drug: [14C]-ONO-5788

First Posted Date: 2019-02-21

Last Posted Date: 2019-11-07

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 12

Registration Number: NCT03849872

Locations: 🇳🇱
PRA-EDS, Groningen, NZ, Netherlands

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: ONO-7475
Drug: ONO-7475 + ONO-4538

First Posted Date: 2018-11-05

Last Posted Date: 2023-10-04

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 24

Registration Number: NCT03730337

Locations: 🇯🇵
Tokyo Clinical Site, Tokyo, Japan

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

Phase 1

Terminated

Conditions: Acromegaly

Interventions: Drug: ONO-5788
Drug: ONO-5788 Placebo
Drug: Octreotide

First Posted Date: 2018-06-27

Last Posted Date: 2019-06-05

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 76

Registration Number: NCT03571594

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: ONO-7579

First Posted Date: 2017-06-09

Last Posted Date: 2019-09-13

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 1

Registration Number: NCT03182257

Locations: 🇺🇸
Greenville Hospital System University Medical Center, Greenville, South Carolina, United States
🇺🇸
Mount Sinai, New York, New York, United States
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom

and more 2 locations

A Study of ONO-7475 in Patients With Acute Leukemias

Phase 1

Terminated

Conditions: Acute Leukemia
Myelodysplastic Syndromes

Interventions: Drug: ONO-7475 6mg once daily
Drug: ONO-7475 3mg once daily
Drug: ONO-7475 10mg once daily
Drug: ONO-7475 6mg + Venetoclax (70-400mg)

First Posted Date: 2017-06-05

Last Posted Date: 2024-07-15

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 42

Registration Number: NCT03176277

Locations: 🇺🇸
The Ohio State University (OSU), Columbus, Ohio, United States
🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy